CFO Matt Abernethy projected INGREZZA sales for 2025 to range between $2.5 billion and $2.6 billion, reflecting $250 million growth at the midpoint. He noted increased competitive pressure and ...

As with other drugs, Ingrezza (valbenazine) can cause side effects, such as drowsiness and parkinsonism. If you are unable to tolerate Ingrezza’s side effects, talk with your doctor or ...

The FDA has approved Neurocrine Bioscience’s Ingrezza, the first ever licensed treatment for tardive dyskinesia or TD. The condition is characterised by uncontrollable movement of the body or ...

Ingrezza remains the main revenue driver ... The company also anticipates R&D expenses to range between $960 million and $1.01 billion. Supported by strategic partnerships and ongoing clinical ...

The payer coverage changes suggests gradually increasing stringency around Ingrezza utilization, which may help explain Q4 weakness and the company’s disappointing FY25 guidance, the analyst ...